Structural neuroimaging biomarkers for obsessive-compulsive disorder in the ENIGMA-OCD consortium: medication matters

Bruin, Willem B; Taylor, Luke; Thomas, Rajat M; Shock, Jonathan P; Zhutovsky, Paul; et al; Brem, Silvia; Brandeis, Daniel; Walitza, Susanne

doi:10.1038/s41398-020-01013-y

Citations

Citation copied

Bruin, W. B., Taylor, L., Thomas, R. M., Shock, J. P., Zhutovsky, P., et al, Brem, S., Brandeis, D., & Walitza, S. (2020). Structural neuroimaging biomarkers for obsessive-compulsive disorder in the ENIGMA-OCD consortium: medication matters. Translational Psychiatry, 10(1), 342. https://doi.org/10.1038/s41398-020-01013-y

Abstract

No diagnostic biomarkers are available for obsessive-compulsive disorder (OCD). Here, we aimed to identify magnetic resonance imaging (MRI) biomarkers for OCD, using 46 data sets with 2304 OCD patients and 2068 healthy controls from the ENIGMA consortium. We performed machine learning analysis of regional measures of cortical thickness, surface area and subcortical volume and tested classification performance using cross-validation. Classification performance for OCD vs. controls using the complete sample with different classifiers an